STSA-1005 injection gains approval from the U.S. FDA to conduct clinical trials

2021-09-22T12:10:39-08:00

STSA-1005 injection gains approval from the U.S. FDA to conduct clinical trials Staidson BioPharma Inc., a wholly-owned subsidiary of Staidson (Beijing) Biopharmaceutical Co., Ltd. received a notification from the Food and Drug Administration (FDA) approving the use of STSA-1005 injection for clinical trials in the treatment of severe COVID-19 indications.

STSA-1005 injection gains approval from the U.S. FDA to conduct clinical trials2021-09-22T12:10:39-08:00

STSA-1002 injection gains approval from the U.S. FDA to conduct clinical trials

2021-09-22T12:10:06-08:00

STSA-1002 injection gains approval from the U.S. FDA to conduct clinical trials Staidson (Beijing) Biopharmaceutical Co., Ltd. has received approval from the U.S. Food and Drug Administration (FDA), for the use of STSA-1002 injection, and independently developed antagonist of complement receptor signaling for the treatment of COVID-19 indications.

STSA-1002 injection gains approval from the U.S. FDA to conduct clinical trials2021-09-22T12:10:06-08:00
Go to Top